6-MAPBT

6-MAPBT, also known as 6--1-benzothiophene, is a possible entactogen of the phenethylamine, amphetamine, and benzothiophene families related to MDMA.
It acts as a monoamine releasing agent and serotonin receptor modulator. The drug's values for monoamine release are 57nM for serotonin and 71nM for dopamine. It is also a potent agonist of the serotonin 5-HT_1B receptor, with an of 24nM, and is a potent antagonist of the serotonin 5-HT_2B receptor, with an of 72nM. Conversely, it is far weaker as an agonist of the serotonin 5-HT_2A receptor and is inactive at the serotonin 5-HT_1A receptor. In addition to the preceding actions, the drug is a monoamine oxidase A inhibitor, with an of 945nM.
It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents. However, benzothiophenes like 6-MAPBT, despite their induction of dopamine release, are said to lack hyperlocomotion or stimulant-like effects in rodents.
6-MAPBT has been studied and patented by Matthew J. Baggott at Tactogen. The drug has also been patented by Mydecine and given the developmental code name MY300.